Hypoxia imaging with 18F-Misonidazole PET in brain metastasis

Hypoxia imaging with 18F-Misonidazole PET in brain metastasis - Hypoxia imaging with FMISO PET in brain metastasis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014572

Enrollment

Registered

2014-07-22

Start date

2014-08-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic brain tumor

Interventions

FMISO PET imaging

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)metastatic brain tumor whose maximum diameter is equal to or above 5mm in MRI. 2)no treatment history with radiotherapy or surgery to metastatic brain tumor. 3)no meningitis carcinomatosa and dissemination in MRI. 4)KPS equal to or above 70%. 5)Pathologically (histologically or cytologically) proven diagnosis from extra cranial lesion. 6)Patients must sign a study-specific informed consent prior to study entry.

Exclusion criteria

Exclusion criteria: 1)patient who can rest in dorsal position for about one hour 2)patient with severe claustrophobia 3)nonage 4)expectant and nursing mothers 5)patient judged unsuitable as a trial subject by the principal investigator

Design outcomes

Primary

Measure	Time frame
SUV(Standardized Uptake Value),lesion to cerebellum ratio,Tumor/blood ratio	—

Secondary

Measure	Time frame
local control survival rate, overall survival rate	—

Countries

Japan

Contacts

Public ContactTakashi Mori

Hokkaido University Hospital Department of Radiation Oncology

tamori-tym@umin.ac.jp011-706-5977

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026